# CheckMate 9DX (NCT03383458)

> A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03383458
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Hepatocellular Carcinoma; Liver Cancer
- Interventions: Nivolumab; Placebo
- Enrollment: 545
- Primary outcome: Recurrence-free Survival (RFS)

## Commentary we found

- Podcasts: 5
- YouTube: 2
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=checkmate-9dx-nct03383458

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03383458", "email": "<work email>"}; the inbox owner confirms by the emailed link.